目的:探讨左乙拉西坦(Lev)添加剂量治疗难治性癫痫的疗效和安全性。方法:采用开放性自身对照方法,对48例(儿童23例,成人25例)难治性癫痫患者进行Lev添加治疗,并随访1年以上,收集治疗后患者发作频率变化、无发作情况、不良反应以及退出原因。结果:Lev治疗难治性癫痫总有效率为64.58%,成人有效率高于儿童,对部分性癫痫综合征有效率高;3、6和12个月无发作率分别为6.25%、18.75%和16.67%,保留率为81.25%、56.25%和43.75%。总不良反应发生率为39.58%,无严重不良反应,退出的最主要原因为对疗效欠满意。结论:LEV是一种安全有效的难治性癫痫治疗药物,对部分性和全面性癫痫发作均有效。
Aim: To evaluate the efficacy and safety of levetiracetam (Lev) as adjunctive therapy for refractory epilepsy. Methods: An open-label, own control study were explored for 48 cases refractory epilepsy patients (23 children and 25 adults). Patients were administered the maximum-effective Lev dose as adjunctive therapy and followed up for at least one year. The clinical data including seizure frequency, adverse effects and exit reasons were collected. Results: 64.58% patients had more than 50% reduction in seizure frequency, and the ratio in adults was higher than children' s. 6.25%, 18.75%, 16.67% patients got seizure free in 3 months, 6 months and 1 year, and the retention rate was 81.25%, 56.25%, 43.75% respectively. 39.58% patients reported one or more adverse effects, but no serious adverse effect appeared. The most common exit reason was not satisfying with the efficacy. Conclusion: Lev is effective and safe as adjunctive therapy for refractory epilepsy, and it is useful for both partial epilepsy and generalized epilepsy.